Indolent B-Cell Lymphoma
Indolent B-Cell Lymphoma
The latest news, research, and perspectives in indolent B-cell lymphoma. This diverse group of slow-growing non-Hodgkin lymphomas form in B cells and include follicular lymphoma, hairy cell leukemia, and marginal zone lymphoma.
Advertisement
Loretta Nastoupil, MDVideo Insights | September 15, 2023
September is Leukemia and Lymphoma Awareness Month, with Lymphoma Awareness Day marked on September 15.
View More
Loretta Nastoupil, MDMeeting News | September 10, 2023
The phase II study evaluated liso-cel in patients with relapsed or refractory follicular lymphoma.
Leah LawrenceIndolent B-Cell Lymphoma | September 1, 2023
The bispecific antibody mosunetuzumab in relapsed or refractory follicular lymphoma continues to show durable responses.
Leah SherwoodAcute Myeloid Leukemia | July 17, 2023
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
Leah SherwoodAggressive B-Cell Lymphoma | July 12, 2023
The CAR-T targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies.
Cecilia BrownVideo Insights | June 7, 2023
Dr. Dickinson discusses major updates to be presented during the 2023 European Hematology Association Congress.
Advertisement
Keightley AmenIndolent B-Cell Lymphoma | June 4, 2023
Lisaftoclax alone or combined with ibrutinib/rituximab demonstrated measurable effects.
Cecilia BrownIndolent B-Cell Lymphoma | June 4, 2023
Pola-R-CHP and R-CHOP “demonstrated similar safety profiles” in older adults with previously untreated DLBCL.
Blood Cancers Today Staff WritersVideo Insights | January 17, 2023
The panel discusses new targets for DLBCL and FL and shares what excites them about the future for these diseases.
Blood Cancers Today Staff WritersVideo Insights | January 13, 2023
The panel discusses regulatory hurdles and patient access considerations for non-Hodgkin lymphoma therapies.
Blood Cancers Today Staff WritersVideo Insights | January 12, 2023
The panel discusses treatment sequencing after CAR-T or transplant and the role bispecifics and other regimens may play.
Blood Cancers Today Staff WritersVideo Insights | January 12, 2023
The panel discusses combination therapy options for patients with DLBCL and FL.
Blood Cancers Today Staff WritersVideo Insights | January 9, 2023
The panel discusses novel treatment options for FL, including bispecifics, CAR-Ts, monoclonal antibodies, and more.
Blood Cancers Today Staff WritersVideo Insights | January 9, 2023
The panel talks about novel therapies for DLBCL, including the timing and sequencing for such treatments and more.
Blood Cancers Today Staff WritersVideo Insights | December 21, 2022
The panel discusses barriers to improving treatment options for patients with DLBCL and follicular lymphoma.
Blood Cancers Today Staff WritersVideo Insights | December 21, 2022
A panel discusses the unmet needs and emerging therapeutic areas for DLBCL and follicular lymphoma.
Leah SherwoodMyeloma | December 1, 2022
At Blood Cancers Today, we have compiled the year's top content awards as doled out by the Twitterverse. 
Leah SherwoodPrint | November 23, 2022
Manali Kamdar, MD; and Craig S. Sauter, MD, FACP; debate CAR T-cell therapy and AHSCT in second-line DLBCL.
Cecilia BrownIndolent B-Cell Lymphoma | November 15, 2022
Patients with LBCL received prophylactic anakinra to reduce the risk of cytokine release syndrome following CAR-T.
Leah SherwoodIndolent B-Cell Lymphoma | October 12, 2022
Orelabrutinib monotherapy may be an option for relapsed/refractory Waldenström’s macroglobulinemia.
Advertisement
Advertisement
Editorial Board